BLOOD GLUCOSE LOWERING EFFECT OF GLIBENCLAMIDE TRANSFERSOME IN RATS (RATTUS NORVEGICUS)

• Main Author: Adawia, Rabiyatul
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/80324
• Institution: Institut Teknologi Bandung

Introduction and objectives: Glibenclamide has been reported as a therapeutic agent for type 2 DM with side effects of severe to fatal hypoglycemia and gastrointestinal disturbances, including nausea, vomiting and heartburn after oral administration. The transfersome is an ultradeformable artificial vesicle that is well known for its potential in topical drug delivery. This vesicle has been selected as a carrier in Trandermal Drug Delivery System to avoid side effects of Glibenclamide drug during oral administration. Methods: The transfersome was prepared by thinlayer hydration method. The transfersome suspension was then characterized for particle size, polydispersity index, entrapment efficiency, and vesicle morphology. Gel containing glibeclamide transfersome was prepared with Carbopol 940 base at a concentration of 1% for activity test to reduce blood sugar level of rats. Results: The transfersome suspension has produced a particle size of 379.9, polydispersity index of 0.321, % entrapment efficiency of 98.03%. The results of activity tests on reducing blood sugar levels of rats showed that the transfersome gel treatment group was able to reduce the blood sugar levels of rats to normal values within 2 weeks without any rats experiencing hypoglycemia while in the oral glibenclamide group reduced sugar levels was profound with one rat having blood sugar levels of 40 mg/dL. Conclusion: Transfersome gel is able to provide activity to reduce blood sugar levels in rats (Rattus norvegicus) during 15 days of administration without experiencing hypoglycemia.